Panagiotis Konstantinopoulos

Panagiotis Konstantinopoulos is a gynecologic oncologist and translational researcher who has investigated the biological rationale for combining PARP inhibitors with checkpoint inhibitors: PARP inhibitor-induced DNA damage activates the cGAS-STING innate immune pathway, increasing interferon signaling and tumor immunogenicity. He has led clinical trials of olaparib plus durvalumab and other PARP+IO combinations in ovarian and endometrial cancer and has contributed to biomarker analyses predicting which patients benefit from this dual strategy. His work bridges DNA repair biology with tumor immunology.